Memphasys Ltd (AU:MEM) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Australian biotech firm Memphasys Limited has announced the patent filing for RoXsta™, an innovative system designed to rapidly measure oxidative stress, potentially transforming diagnostics across various fields. The prototype, although not ready for point-of-care use, promises quick results and is undergoing field testing and industry studies to validate its effectiveness. With its versatility and speed, RoXsta™ aims to be a game-changer for healthcare professionals and industries requiring immediate oxidative stress assessment.
For further insights into AU:MEM stock, check out TipRanks’ Stock Analysis page.